Previous 10 | Next 10 |
Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data from Either Interim Analysis May Support an NDA Submission in the ...
NuCana recently enrolled the required number of patients to conduct a first interim analysis in Acelarin‘s Phase III study in biliary tract cancer in the 1H of 2022. Acelarin has both the FDA's Fast Track Designation and Orphan Drug Designation. The company publicized suppl...
Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022 Received Fast Track Designation from FDA for Acelarin for the Treatment of Patients with Biliary Tract Cancer Announced Additi...
EDINBURGH, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference. Eve...
EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr....
Gainers: Alzamend Neuro (NASDAQ:ALZN) +52%, Progenity (NASDAQ:PROG) +18%, OptimizeRx (NASDAQ:OPRX) +15%, Atea Pharmaceuticals (NASDAQ:AVIR) +14%, Perrigo (NYSE:PRGO) +11%. Losers: Corvus Pharmaceuticals (NASDAQ:CRVS) -15%, NuCana (NASDAQ:NCNA)...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “NuCana PLC Receives FDA Fast Track Designation for Acelarin” NuCana PLC (NASDAQ: NCNA) surged over 26% in premarket trading after the U.S. Food and Drug Administra...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Paltalk (NASDAQ: PALT ) is rocketing higher on Wednesday as traders flock to the stock following an update from the company today. Source: Shutterstock Paltalk announced today that it has brought on ClearThin...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NuCana (NASDAQ: NCNA ) stock is surging higher on Wednesday after the company revealed fast track designation from the U.S. Food and Drug Administration (FDA) for Acelarin. Source: Bukhta Yurii / Shutterstock.com ...
Gainers: NuCana NCNA +24%, GeoVax Labs (NASDAQ:GOVX) +11%, NanoVibronix (NASDAQ:NAOV) +9%, Regencell Bioscience (NASDAQ:RGC) +11%, Petros Pharmaceuticals (NASDAQ:PTPI) +7%. Losers: Editas Medicine EDIT -15%, Annexon (NASDAQ:ANNX) -15%, Happine...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...